Clinical Trial Update: Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update for oral sodium fusidate (CEM-102) in refractory bone or joint infections has completed, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone and Joint Infections
• Osteomyelitis
• Septic Arthritis

Drugs mentioned

• sodium fusidate (CEM-102) (sodium fusidate)

Snippet

Sponsor: Arrevus Inc. | Conditions: Refractory Bone or Joint Infections | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-01-30